Documented evidence of the FDA’s relentless war against a proven cure for cancer

Summary:

Over the past 50 years, many cancer patients have been successfully treated by a product developed by a Polish doctor, Stanislaw Burzynzki, MD PhD, in 1967. Through his cancer research, he discovered a new group of small peptides in the human body. Later, he discovered that people diagnosed with cancer consistently had very low levels of these peptides.

Peptides are fundamental biological molecules that play crucial roles in various physiological processes within the human body. They are essentially short chains of amino acids, which are the building blocks of proteins, linked together by peptide bonds.

Dr. Burzynzki hypothesized that replenishing these peptide levels could potentially cure them from cancer. He learned to synthesize these peptides and developed a product to do that, which he called Antineoplastons. He patented it and launched a publicly traded corporation, and entered the United States Food & Drug Administration (FDA) clinical trial process to get Antineoplastons approved for market through his newly formed pharmaceutical company, Burzynski Research Institute, Inc. And that’s when the FDA launched their attack.

The following is an AI generated summary of the 106-minute video shown above, which is Part 2 of a 2-part series published on April 17, 2024 by Best Documentary’s YouTube Channel. See Part 1.

Dr. Burzynski’s Treatment Approach

• Dr. Burzynski’s treatment led to remission for many patients, yet he faces legal challenges with potential federal imprisonment.
• FDA scrutiny and legal battles have hindered the recognition of Dr. Burzynski’s breakthrough in cancer treatment.

Dr. Burzynski saved my life, but he is now facing 300 years in a federal penitentiary. Perhaps he has found the medical breakthrough of the century, but how will we know if the FDA succeeds in quashing it?

FDA’s Actions and Patient Access to Treatment

• The FDA has repeatedly targeted Dr. Burzynski’s clinic, prompting questions about the agency’s motives and expenditures.
• Patients face obstacles in accessing Dr. Burzynski’s treatment due to stringent FDA regulations and the need for prior failed chemotherapy and radiation.

“How much money has the FDA spent in the last 10 years to put Dr. Burzynski out of business? How many more grand juries must he go through, and why can’t advanced cancer patients choose their treatment?”

Personalized Gene-Targeted Cancer Therapy

• Dr. Burzynski’s approach involves personalized gene-targeted therapy for patients, aiming to treat each individual’s unique genetic markers related to cancer.
• This personalized treatment strategy recognizes cancer as a complex interplay of various molecular diseases, requiring tailored medication combinations based on genomic studies.

“Cancer is not just a single disease but possibly half a million different molecular diseases, necessitating individualized treatment for each patient based on their genetic makeup.”

Medical Professionals’ Response to Burzynski’s Treatment

• Drug representatives are intrigued when informed about Burzynski using their medications for various cancers previously deemed incurable by other doctors, such as Merkel cell cancer.
• Despite traditional medical education not covering such unconventional applications, Dr. Burzynski’s approach has shown lasting benefits for cancer control.

“He’s out of the box, and that’s what Mrs. Wright needed. She needed some fresh ideas, and that’s resulted in her success.”

Personal Testimonies and Financial Challenges

• The high cost of Burzynski Clinic’s gene-targeted medications, exceeding $100,000 annually, poses financial difficulties as insurance generally does not cover them.
• Patients often face challenges affording treatment or finding alternative solutions due to the lack of insurance coverage for the unconventional therapy.

“Insurance doesn’t cover Burzynski since his technique is not widely accepted, so most patients must start therapy at his clinic and then return to their local oncologists in the hope of obtaining full insurance coverage.”

Limitations of Conventional Treatment Approaches

• Lindsay’s case highlights the controversy surrounding Burzynski’s regimen compared to traditional chemotherapy, with uncertainty regarding the life-saving potential of his treatment.
• Despite claims of effectiveness from patients, traditional medical establishments like MD Anderson remain cautious due to the lack of comprehensive evidence supporting Burzynski’s methods.

“It is impossible to know for certain if Burzynski’s regimen would have saved Lindsay’s life; the only certainty is that she was denied the opportunity to explore his treatment by her insurance company and local oncologist.”

Criticism of Existing Clinical Trial Structure

• Dr. Burzynski believes that big institutions may resist his treatments because they don’t like being outshone by an outsider.
• Mainstream oncological centers face bureaucratic barriers when considering new personalized treatment methods.
• The current clinical trial paradigm hinders the approval of personalized regimens that consider individual patient genetics.

Big institutions may not embrace innovative treatments due to a reluctance to be overshadowed by outsiders.

Challenges in Customizing Cancer Treatments

• Customizing treatments based on a patient’s genetic makeup is crucial for effective cancer therapy.
• Combining multiple medications tailored to an individual’s genetic profile challenges the traditional one-size-fits-all approach in clinical trials.

“If you tried to work that through the current system, it just doesn’t fit… I don’t think it would work with the system.”

Limited Understanding of Personalized Medicine

• Many oncologists may struggle to grasp the concept of personalized medicine based on genetic markers.
• Understanding the link between genes and cancer could revolutionize treatment efficacy and change the outlook of cancer therapy.

“Most oncologists don’t understand… if they understood that, they have a lot of things available to treat patients successfully.”

Laura’s Decision to Pursue Burzynski Clinic

• Laura decided to explore alternative treatment at the Burzynski Clinic after conventional therapies failed against her aggressive brain tumor, despite skepticism from some, including her oncologist and loved ones.
• She believed the clinic’s treatment could offer hope for survival when other options seemed limited.

Some people don’t survive chemotherapy. What’s the point in Laura’s last days being in such pain and being so ill? – Laura wanted to explore options beyond conventional treatments, seeking a chance at a better quality of life.

Research and Controversy Surrounding Burzynski Clinic

• Initially met with skepticism and criticism, Laura and her husband conducted thorough research, including speaking with others who had experience with Dr. Burzynski.
• Despite encountering negative opinions labeling the clinic as a scam, they found firsthand accounts validating the treatment’s potential.

There’s like a lot of websites calling him a scammer, a quack… I’d read for days and days about Dr. Burzynski, finding someone who’ actually been there to verify it was crucial for us.

Laura’s Meeting with Her Oncologist

• Laura, Ben, and Laura’s parents sought reassurance from Laura’s oncologist regarding the continuation of her medical care upon their return from the Burzynski Clinic in the U.S.
• The oncologist expressed hesitation towards the unconventional approach, emphasizing that the NHS did not support the clinic’s treatment.

I knew it would be a very interesting conversation because we knew he was against what we were doing… for legal reasons, we cannot disclose the name of Laura’s oncologist or the hospital where the meeting took place.

Discussion on Burzynski’s Treatment and NHS Support

• Laura’s oncologist highlighted the controversy surrounding Dr. Burzynski’s methods, expressing concerns about the lack of scientific backing for his treatment.
• NHS coverage for treatment at the Burzynski Clinic was discussed, with the oncologist emphasizing that NHS resources wouldn’t cover costs associated with treatments at the clinic.

…I’m personally not entirely convinced that this is a read that as an NHS oncologist… we’re looking at treating Laura in a different way… the National Health Service unfortunately won’t be able to cure our daughter’s tumor in the long term.

Seeking Alternative Treatments

• Some individuals seek hope in unconventional treatments, even asserting that if a method were ineffective, it would not have FDA approval.
• Despite ethical concerns raised by some, there are those who find hope in the unconventional treatments offered by Dr. Burzynski.

Seeking hope elsewhere and if it was a quack, total quack, he wouldn’t have FDA approval. I completely hear what you say.

Support for Dr. Burzynski’s Protocols

• Dr. Burzynski’s treatment protocols have shown promising results, especially in phase three trials for specific types of cancer.
• Comparisons between Dr. Burzynski’s results and conventional cancer treatments suggest that his approach is yielding impressive outcomes.

Because at the end of the day, he’s got here the strict protocols to be in these trials, especially to be in phase three for a particular type of cancer and I think his results are amazing.

Personal Testimonials and Varied Experiences

• Personal accounts of patients who have received treatment from Dr. Burzynski vary, with some reporting positive outcomes and others showcasing inconsistencies in care.
• The experience of individuals receiving treatment from Dr. Burzynski demonstrates the diverse responses to his methods, with some showing notable improvements.

We’ve got a friend who’s been to the clinic two, three years ago, she was under your care. She’s been to the clinic, she’s an expen[sive] patient, and she’s had great results.

Challenges and Ethical Considerations

• There are differing opinions regarding Dr. Burzynski’s individualized care plans, with some expressing concerns about entering clinical trials solely to access specific treatments.
• The conversation highlights ethical dilemmas and differences in perspectives regarding the appropriateness of certain treatments or care plans.

I personally have a problem with Dr. Burzynski and the individual care plans that he’s been delivering. So, we do differ in our understanding of what is a problem or not a problem.

Ben’s Fundraising Initiative

• Ben initiated a fundraising campaign called the “Hope for Laura Fund” to raise £80,000 for a young mother’s cancer treatment in the U.S.
• His social media outreach garnered significant support, and within weeks, they raised the required amount for the treatment.

“If only one in five gave a couple of quid, then this afternoon we could have saved a woman’s life.”

Ben’s Dedication to Helping Laura

• Ben’s commitment involves managing a rigorous dosing schedule for Laura, with medications needing to be administered every four hours.
• The process involves frequent bag changes and significant time investment, showcasing his unwavering dedication to Laura’s treatment.

“I think one of the biggest things for me was the fact that I went over there with her and I took part in this.”

Challenges Faced by Other Patients

• Ben and Laura offer support and advice to others facing similar medical challenges, encouraging them to conduct thorough research before making treatment decisions.
• They emphasize the importance of autonomy and critical thinking in deciding on treatment options, acknowledging the complexity and uncertainty individuals may encounter.

“You’ve got to do a lot of research, read between the lines, make your own mind up.”

Transformation in Hannah’s Treatment Journey

• Hannah receives positive news of a 10% reduction in her tumor size, reflecting a promising development in her treatment progress.
• Following months of treatment, Hannah’s tumor diminishes by 63%, showcasing the effectiveness of the therapy in her case.

“My tumor has already shrunk by 10%… absolute amazing.”

Positive Impact of Treatment on Laura’s Life

• Laura’s treatment journey results in significant improvements in her quality of life, enabling her to engage in everyday activities with renewed energy and vitality.
• The treatment not only combats the physical challenges of cancer but also revitalizes her spirit, allowing her to plan for the future with newfound optimism.

“It’s slowly brought me out of this dark hole… we’ve planned our wedding now, which is next year.”

Hannah’s Progress and Hope for the Future

• The mother expresses acceptance of the controversial treatment due to the desperate situation her daughter faces.
• Hannah remains optimistic about her future despite needing ongoing scans.
• The family experiences a positive shift in outlook as Hannah shows progress and smiles.
• Dr. Burzynski acknowledges the varying outcomes of the treatment, highlighting the ongoing effort to understand its effectiveness.

Hannah’s optimistic outlook and the family’s positive shift in perspective reflect the hope that comes with seeing progress despite the ongoing challenges.

Dealing with Brain Stem Goma and Treatment Options

• Brain stem Goma is described as a fatal condition, especially in children, with limited effective treatments.
• The rarity and severity of brain stem Goma result in grim survival statistics for patients.
• The family’s decision to pursue Dr. Burzynski’s treatment is driven by the lack of promising alternatives for their child’s condition.

“Brain stem Goma is a fatal disease, particularly harsh in children, leaving families with limited options and little hope for survival.”

Emotional Support and Decision-Making in a Similar Situation

• The support network formed by families facing similar challenges provides valuable emotional support and practical advice.
• Sharing experiences with other parents facing similar situations helps in decision-making and provides a sense of solidarity.
• Encouraging other families to consider alternative treatments like Burzynski’s is driven by the belief in exploring all options for their children’s well-being.

“In times of uncertainty, the strong support system of families facing similar struggles plays a crucial role in guiding decisions and providing emotional strength.”

Burzynski’s Experimental Gene Therapy Treatment

• The video showcases Tori Marino’s journey, where traditional treatments failed, and the parents opted for an experimental gene therapy approach by Dr. Burzynski.
• Despite initial pessimism from doctors, the treatment showed promise, with scans indicating a 20 to 25% reduction in the tumor size within a few months of treatment initiation.

“I just was just baffled at the way they weren’t giving Dr. Burzynski all the credit for this.”

Success of Anti-Neoplastons in Pediatric Brain Tumor Trials

• Reports from Phase 2 trials of anti-neoplastons in pediatric brain tumors demonstrated a 25% survival rate beyond 5 years, outperforming traditional treatments.
• This success contrasted with zero survivors in trials using standard chemotherapy and radiation, highlighting the potential of anti-neoplastons.

“America’s National Cancer Institute began publicly citing and acknowledging the peer-reviewed anti-neoplaston trials, signaling their importance.”

Accelerated Drug Approval Process

• Accelerated drug approval for anaplastic astrocytoma and glioblastoma brain cancers was based on single-arm Phase 2 studies with encouraging responses, despite limited data from randomized controlled trials on clinical benefits.
• Quote: > Drug approval for brain cancers was granted based on limited data from trials, raising concerns about the effectiveness of the accelerated approval process.

Challenges with FDA Approval Process

• The FDA’s focus on quick drug approvals, influenced by industry funding, has shifted attention from rigorous evaluations of drug efficacy and safety.
• Quote: > The FDA’s emphasis on speed in drug approvals, driven by industry contributions, has led to a shift in priorities away from thorough evaluation processes.

Impact of Pharmaceutical Influence

• Interconnected relationships between FDA regulators and pharmaceutical industry executives may compromise the impartiality of drug approval processes.
• Quote: > The revolving door between FDA regulators and pharmaceutical executives can influence drug approval decisions, potentially affecting public health.

Business Interests in Drug Approval

• Business strategies aim to limit competition by hindering alternative treatments from entering the market, potentially affecting patient access to innovative therapies.
• Quote: > Drug companies may use various tactics, including limiting competition, to maintain market dominance and control over drug availability.

Regulatory Challenges in Drug Development

• The intertwining relationships between regulatory bodies and pharmaceutical companies could create conflicts of interest and impact the impartiality of drug approval processes.
• Quote: > Close links between regulators and pharmaceutical executives can raise questions about fair practices and transparency in drug approval processes.

Hospital Refusals and Reasons

• Hospitals in the United States, Canada, and England declined to participate in phase three trials for brain stem Goma, citing various reasons such as concerns about patients self-administering therapy at home, the mandatory inclusion of radiation therapy with known side effects, and fear that parents wouldn’t approve due to the therapy’s inventor’s legal history.
• Quote:
  

  “A common reason some hospitals refused the study was disinterest, while others objected to patients managing therapy at home or radiation’s adverse effects on children.”

Challenges in Conducting Clinical Trials

• Conducting randomized trials for new therapies faces obstacles, particularly if the standard treatment offers no hope of success, making a randomized design with a control group difficult, especially in pediatric oncology.
• The reputation of the therapy’s inventor, who has clashed legally with the FDA, further complicates recruitment, with hospitals wary of potential backlash and patient reluctance.
• Quote:
  

  “Randomized trials face challenges when standard treatments offer no success, compounded by the inventor’s legal battles, deterring hospitals and patients from participating.”

Criticisms and Patient Perception

• Dr. Burzynski engenders a devoted following among patients, with testimonies suggesting a cult-like loyalty and dependency, resembling characteristics seen in cult dynamics where followers heavily rely on the leader.
• Patients express deep emotional connections to Dr. Burzynski, often defending him vehemently against critics and mirroring traits of cult followers who exhibit unwavering devotion and dependency on the cult leader.
• Quote:
  

  “Patient testimonials hint at a cult-like atmosphere, where followers show intense loyalty and reliance on Dr. Burzynski, reflecting traits seen in cult relationships.”

Controversy Surrounding Burzynski Clinic Practices

• Skeptics criticize the Burzynski Clinic for charging upfront fees for therapy, as insurance commonly rejects covering these costs, leading to patients signing gag orders due to insurance disputes and staff receiving payments discretely.
• Assertions suggest that the clinic avoids sharing the financial burdens and risks typical of research endeavors, illustrating a departure from standard research practices in the medical industry.
• Quote:
  

  “Critics question the Burzynski Clinic’s upfront fees, leading to insurance disputes and staff receiving secret payments, raising concerns about the clinic’s practices.”

Cost of Burzynski Treatment Comparison

• The Wall Street Journal exposed how nonprofit hospitals like MD Anderson demanded $115,000 upfront from a patient before treatment.
• Comparing Burzynski’s $110,000 monthly treatment cost to an $800,000 bill for one month of chemotherapy showcases relative affordability.
• The skepticism and criticisms around Burzynski’s high treatment costs and payment methods are based on misconceptions and comparisons with conventional treatments.

“The reason why he can’t do his trials is because it cost $200 million, I don’t know where they’re getting that number.”

Criticism of Burzynski Clinic on Wikipedia

• Wikipedia’s Burzynski Clinic page is accused of being biased, with skeptics allegedly blocking neutral contributions.
• The skeptic behind the Wikipedia article is vilified for sensationalizing patient deaths and receiving funding from various entities critical of Burzynski.

“The Skeptics have hijacked and locked the Wikipedia page on the Burzynski clinic blocking all neutral contributions…”

Challenges in Publishing Burzynski’s Trials

• The Lancet rejected a study on patients surviving long-term with glioblastoma after treatment with antineoplastons, raising questions about publication bias.
• The Scientific Community’s reluctance to publish findings on antineoplastons hinders global dissemination and acceptance of Burzynski’s treatments.

“The reason for the Lancet’s rejection was simply we have decided not to publish it because we believe the message would be better elsewhere.”

Clinical Trial Results on Antineoplastons

• Antineoplastons showed promise in cancer treatment, with a significant response rate in about 50% of studied patients.
• The phase one trial led to a phase two study focusing on liver cancer and demonstrated improved disease-free intervals and longer overall survival with antineoplastons.

“The AS2-1 could obviously prolong disease-free interval and overall survival, so we moved to the prospective randomized clinical trial.”

Biomedical Research and Money Influence

• Institutions, including universities and pharmaceutical companies, may lack incentives to find a cure for cancer due to financial interests and funding dependencies.
• The monetary landscape influences biomedical research priorities and could hinder radical breakthroughs in treatments or cures for diseases like cancer.

“Money wins, money votes, money does everything and it controls our government.”

Pharmaceutical Industry Practices

• The pharmaceutical industry’s main motive is profit, not purely the well-being of patients. The most profitable drugs are those that require life-long consumption, ensuring a continuous revenue stream for the companies.
• Quote: > The best drugs in the Pharma world are the ones that people have to continue taking forever and ever and ever and ever.

Medical Breakthroughs and Financial Barriers

• Historical medical breakthroughs like insulin and penicillin have significantly improved healthcare. Yet, the lack of recent major breakthroughs is attributed to financial concerns. New therapies that overshadow existing ones risk disrupting profits.
• Quote: > Today, medical breakthroughs put at risk the entire financial underpinnings.

Lack of Awareness Movements for Diseases

• Unlike cancer, diseases like diabetes and pneumonia lack the extensive public awareness campaigns. Increasing disease awareness isn’t synonymous with finding cures, illustrating a significant gap in disease-focused awareness efforts.
• Quote: > There was no movement to increase the awareness of diabetes. There is no need for any movement to increase your awareness of any disease.

Barrier to Novel Therapies Advancement

• The obstruction to introducing superior therapies, like Burzynski’s, lies in the fear of losing profits from existing treatments. This financial risk discourages the development and implementation of groundbreaking medical advances.
• Quote: > Hence we haven’t had any major medical breakthroughs for the last 50 years.

Potential Impact of Revolutionary Medical Treatment

• Burzynski’s innovative cancer treatment has the potential to reshape society’s perception of chronic illnesses, reducing fear and changing the way diseases like cancer are approached and understood.
• Quote: > Can you imagine a society where women are not terrified by mammograms and men are not kind of semi-raped with all this prostate stuff?

The Humanity in Seeking Treatment

• It’s human nature to seek treatments that offer hope for diseases considered fatal. The desire to alleviate suffering and find cures demonstrates a universal aspect of humanity in the face of severe illnesses.
• Quote: > It is only human to want to seek treatment for a disease that is considered to be almost universally fatal.